title: Disposition study of a new potential antineoplastic agent dimefluron in rats using high-performance liquid chromatography with ultraviolet and mass spectrometric detection.
abstract: The disposition of a new potential antineoplastic drug dimefluron after an oral administration to rats was investigated. Dimefluron, 3,9-dimethoxy-5-(2-dimethylaminoethoxy)-7H-benzo[c]fluoren-7-one hydrochloride, was administered in a single oral dose (250 mg kg(-1) of body weight) in the form of an aqueous solution via a gastric probe. Dimefluron metabolites were being searched for in rat faeces. Synthetic standards of the expected phase I metabolites (the products of O- and N-desmethylation, N-oxidation and carbonyl reduction of dimefluron) were prepared and used together with dimefluron and internal standard in the development of two HPLC bioanalytical methods based on different separation principles. The first separation of dimefluron and the phase I metabolites was tested on a 250 mm x 4 mm chromatographic column with LiChrospher 60 RP-selectB 5 microm (Merck) using an isocratic mobile phase containing 0.01 M nonylamine buffer (pH 7.4) and acetonitrile in the 1:2 ratio (v/v). The second separation was performed on a 250 mm x 4 mm chromatographic column Discovery HS F5, 5 microm (Supelco) using a linear gradient mode with the mobile phase containing acetonitrile and phosphate buffer (0.05 M KH2PO4, pH 3). The flow rate was 1 ml min(-1) in both cases. UV detection was performed in the dual wavelength mode, with 317 nm having been used for dimefluron and all 7H-benzo[c]fluoren-7-one metabolites, 367 nm for 7H-benzo[c]fluoren-7-ol metabolites. A higher homologue of dimefluron served as an internal standard. The identity of the dimefluron metabolites in biological samples was confirmed using HPLC-MS experiments. The elimination study showed that the concentration maximum for dimefluron and its metabolites in rat faeces was reached 48 h after the administration of the parent drug. O-Desmethylated derivatives of dimefluron prevailed among the phase I metabolites.
authors.affiliation: Department of Pharmaceutical Chemistry and Drug Control, Faculty of Pharmacy, Charles University, Heyrovského 1203, CZ-500 05 Hradec Králové, Czech Republic.
authors.forename: P
authors.initials: P
authors.lastname: Císar
authors.forename: M
authors.initials: M
authors.lastname: Nobilis
authors.forename: Z
authors.initials: Z
authors.lastname: Vybíralová
authors.forename: M
authors.initials: M
authors.lastname: Holcapek
authors.forename: L
authors.initials: L
authors.lastname: Kolárová
authors.forename: M
authors.initials: M
authors.lastname: Pour
authors.forename: J
authors.initials: J
authors.lastname: Kunes
authors.forename: J
authors.initials: J
authors.lastname: Klimes
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000032:analysis* / Q000737:chemistry* / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D005449:Fluorenes / Q000032:analysis* / Q000737:chemistry* / Q000378:metabolism; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D051381:Rats; D013056:Spectrophotometry, Ultraviolet / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D005449:Fluorenes; C507439:dimefluron; C034234:VUFB 13468